Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

David A. Hyman, MD, JD, on Inclusive Shared Savings

Apr

Today In Oncology

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

David A. Hyman, MD, JD, on Inclusive Shared Savings

Metastatic NSCLC Deep Learning Pathomics Platform May Help Predict Response to Immunotherapy

High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity

Methylation-Based AI Model Classifies Tumors of Unknown Origin

Initial Data Shows Safety for WEE1 PKMYT1 Inhibitor Combination in Advanced Solid Tumors

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?